Allele-specific antisense oligonucleotides designed for spinocerebellar ataxia type 3
Start here
Spinocerebellar ataxia type 3 is a progressive neurodegenerative disease for which no therapy addresses its underlying cause. A study published in Science Translational Medicine on 21 October 2026 reports a single-nucleotide polymorphism–directed strategy for designing allele-specific antisense oligonucleotides against the disease. The approach uses common genetic variants to distinguish the mutant disease-causing allele from the healthy copy, so that the antisense agent silences the harmful allele while sparing normal function. The paper appears in Volume 18, Issue 872 (DOI 10.1126/scitranslmed.adz2140). Details of the experimental design, the supporting data, and the conclusions have not yet been made available, and questions of preclinical efficacy, safety, and path to clinical testing remain open.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- ScienceSingle-nucleotide polymorphism–directed design of allele-specific antisense oligonucleotides for spinocerebellar ataxia type 3
This study uses single-nucleotide polymorphisms to guide the design of allele-specific antisense oligonucleotides for spinocerebellar ataxia type 3. The article appears in Science Translational Medicine, Volume 18, Issue 872 (October 2026), DOI 10.1126/scitranslmed.adz2140. The available material provides only the title and volume information; experimental design, data, and conclusions are not disclosed.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 21 15:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.